Cabozantinib: A Review of Its Use in Patients with Medullary Thyroid Cancer

Preclinical Evaluation of Imaging Biomarkers for Prostate Cancer Bone Metastasis and Response to Cabozantinib

(2014) Timothy J. Graham et al.   JNCI-Journal of the National Cancer Institute

Cabozantinib in Progressive Medullary Thyroid Cancer

(2013) Rossella Elisei et al.   JOURNAL OF CLINICAL ONCOLOGY

In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer

(2013) Frauke Bentzien et al.   THYROID

Cabozantinib for the Treatment of Advanced Medullary Thyroid Cancer

(2012) Madhavi Nagilla et al.   ADVANCES IN THERAPY

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012) F. Pacini et al.   ANNALS OF ONCOLOGY

Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors

(2012) Barbara Sennino et al.   Cancer Discovery

The Effects of Four Different Tyrosine Kinase Inhibitors on Medullary and Papillary Thyroid Cancer Cells

(2011) Hans H. G. Verbeek et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

(2011) Razelle Kurzrock et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS